Adalvo, in partnership with one of the biggest Latvian medicine manufacturers Olpha, announces the first-to-market launch of Nitrofurantoin ER in the Baltic region and will expand availability to additional European markets in the coming months.
Developed in-house, this marks the first generic entry in these markets, despite the formulation patent for the reference product expiring in 2007.
Nitrofurantoin is a trusted first-line antibiotic for urinary tract infections (UTIs). With a well-established safety profile and minimal side effects, it remains a go-to treatment for healthcare providers and patients alike.
The global UTI market is projected to grow from $7.2 billion in 2024 to $14.28 billion by 2031, with a CAGR of 10.23% (Coherent MI).
Anil Okay, CEO of Adalvo, stated: “This launch strengthens our commitment to expanding patient access to high-quality treatments. Partnering with Olpha allows us to address a critical healthcare need while strengthening Adalvo’s leadership in delivering differentiated pharmaceutical solutions.”
"Partnering with Adalvo and other European pharmaceutical companies is crucial in providing availability of new generics because it allows us to accelerate the process, share expertise, and optimize resources. By working together, we can bring high-quality and affordable medicines to patients more efficiently and expand our reach across European markets," stressed Juris Bundulis, CEO of Olpha.
With a clear focus on regulatory excellence and market leadership, Adalvo continues to bring differentiated, patient-centric solutions to the forefront.
Get In Touch Today!